IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Nov 9, 2022 · 10-Q · 40 days after period end · 0000950170-22-023877
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Net Income | -$7.92M | -$21.71M | -$21.51M | -$9.86M |
| EPS Diluted | -$0.22 | -$0.73 | -$0.73 | -$0.37 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end
